Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
17 - Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
from II - Therapeutic Areas
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
Summary
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, with a population prevalence of 2 percent to 3 percent and an annual incidence rate of 0.5 percent to 1.0 percent. Like many autoimmune conditions, it affects women more commonly than men (4:1). The prevalence of RA increases from the third decade through the eighth. Because it is the most common inflammatory rheumatic disease, most pharmacogenetic studies in adult rheumatology have concentrated on treatments for RA, and this will be the focus of the chapter.
Clinically, RA is a painful condition associated with significant disability. It primarily affects the joints, resulting in pain, swelling, and loss of musculoskeletal function. Because of its chronic nature, small changes accumulate and many patients experience substantial disability over the decades that they live with the condition. Although classical extraarticular manifestations (e.g., vasculitis, Felty's syndrome, spine disease) have diminished in frequency, there is an increasing awareness that the inflammation of RA places patients at increased risk for common conditions, such as cardiovascular disease, osteoporosis, and insulin resistance. These chronic comorbidities also contribute to the disability associated with RA.
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 188 - 201Publisher: Cambridge University PressPrint publication year: 2012
References
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief interventionArthritis Rheum 2002 46 347Google Scholar
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritisAm J Hum Genet 2004 75 330Google Scholar
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosusN Engl J Med 2007 357 977Google Scholar
Two independent alleles at 6q23 associated with risk of rheumatoid arthritisNat Genet 2007 39 1477Google Scholar
TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide studyN Engl J Med 2007 357 1199Google Scholar
A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritisPLoS Med 2007 4Google Scholar
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritisNat Genet 2003 34 395Google Scholar
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4Am J Hum Genet 2005 77 1044Google Scholar
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritisArthritis Rheum 2007 56 2202Google Scholar
Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritisPharmacol Rev 2005 57 163Google Scholar
Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapyJ Rheumatol 1998 25 238Google Scholar
Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalitiesAnn Rheum Dis 2005 64 207Google Scholar
Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritisAnn Rheum Dis 2003 62 423Google Scholar
The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patientsArthritis Rheum 2001 44 2525Google Scholar
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymesArthritis Rheum 2006 54 1087Google Scholar
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisArthritis Rheum 2006 54 607Google Scholar
Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexateJ Rheumatol 2006 33 1266Google Scholar
Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritisArthritis Rheum 2006 54 3095Google Scholar
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritisAnn Rheum Dis 2006 65 1213Google Scholar
Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR geneAnn Rheum Dis 2004 63 1227Google Scholar
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritisInt J Mol Med 2003 11 593Google Scholar
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analysesPharmacogenetics 2002 12 183Google Scholar
Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis Rheum 2004 50 2766Google Scholar
Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational studyAnn Rheum Dis 2005 64 1180Google Scholar
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritisArthritis Rheum 2007 56 1765Google Scholar
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet 1999 354 1932Google Scholar
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med 1999 340 253Google Scholar
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet 2004 363 675Google Scholar
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectivenessHealth Technol Assess 2006 10Google Scholar
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum 2006 54 2368Google Scholar
Associations between rheumatoid arthritis and malignancyRheum Dis Clin North Am 2004 30 271Google Scholar
Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitorsRheumatology (Oxford) 2005 44 172Google Scholar
The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte culturesCytokine 2003 23 76Google Scholar
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended reportArthritis Rheum 2005 52 61Google Scholar
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine 1995 7 251Google Scholar
TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritisClin Exp Rheumatol 2004 22 118Google Scholar
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionSemin Arthritis Rheum 2006 36 159Google Scholar
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterRheumatology (Oxford) 2006 45 1558Google Scholar
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanerceptArthritis Rheum 2004 50 2750Google Scholar
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis populationAnn Rheum Dis 2006 65 342Google Scholar
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritisAnn Rheum Dis 2003 62 526Google Scholar
Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patientsArthritis Rheum 2004 50 1077Google Scholar
Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritisJ Rheumatol 2002 29 1847Google Scholar
The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritisRheumatology (Oxford) 2005 44 547Google Scholar
Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritisArthritis Rheum 2003 48 1849Google Scholar
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patientsRheumatology (Oxford) 2007 46 93Google Scholar
Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritisScand J Rheumatol 2004 33 228Google Scholar
Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agentsArthritis Rheum 2005 52 2693Google Scholar
Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritisArthritis Rheum 2007 56 448Google Scholar
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritisAnn Rheum Dis 2007 66 1525Google Scholar
Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritisPharmacogenomics 2007 8 761Google Scholar
Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patientsArthritis Rheum 2004 50 400Google Scholar
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprineAnn Intern Med 1998 129 716Google Scholar
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intoleranceAnn Intern Med 1997 126 608Google Scholar
Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprineJ Rheumatol 2002 29 2507Google Scholar
Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in KoreaRheumatology (Oxford) 2004 43 156Google Scholar
TPMT testing in rheumatology: any better than routine monitoring?Rheumatology (Oxford) 2007 46 727Google Scholar